Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Long-term data on semaglutide now extends beyond five years for diabetes indications and approximately three years for weight management, with ongoing extension studies continuing to accumulate evidence
GLP-1 (Glucagon-like peptide-1): GLP-1 is a peptide hormone secreted by intestinal L cells after food intake, exhibiting multiple physiological effects
An open-label uncontrolled trial including 27 patients with T2D and NAFLD treated with liraglutide 0.9 mg/day for 24 weeks showed a trend toward increases in liver-to-spleen attenuation ratio assessed by CT scan and, more importantly, a significant improvement in histological inflammatory scores in 10 subjects undergoing liver biopsies after a prolonged treatment of 96 weeks (64)
The SCALE trials showed liraglutide 3.0 mg producing approximately 8% body weight loss over 56 weeks, roughly half of what semaglutide achieves
Fat loss While some evidence points to IGF-1s involvement in nutrient partitioning within the body, promoting lean tissue growth over fat storage, this is far less researched than its anabolic effects on muscle tissue
